Speaker Details

Heather Bresch
CEO, Mylan

Heather Bresch is CEO of Mylan, one of the largest generics and specialty pharmaceutical companies in the world. She also serves on the company's board of directors.

Mylan's mission is to provide the world's 7 billion people access to high quality medicine. Over the course of her 20-year career at Mylan, Ms Bresch has championed initiatives aimed at removing barriers to patient access to medicine. Some of her key policy priorities include working to ensure that everyone living with HIV/AIDS has access to treatment; advocating for a viable abbreviated approval pathway for safe, effective and more affordable generic versions of biologic drugs; and ensuring immediate access to critical, life-saving therapies such as Epinephrine auto-injectors, the first-line treatment for life-threatening allergic reactions.

Ms Bresch also has been an advocate for ensuring one quality standard for all drugs sold in the US. She was instrumental in the development of the Generic Drug User Fee Act and is advocating for a needed change to the Federal Food, Drug and Cosmetic Act of 1938 in order to arm the US Food and Drug Administration with the necessary resources and authority to regularly inspect foreign plants. Earlier in her career, Ms Bresch played a vital role in the passage of the 2003 Medicare Modernization Act, which helped to ensure consumer access to affordable pharmaceuticals.

Throughout her career with Mylan, Ms Bresch has held roles of increasing responsibility in more than 15 functional areas. Prior to becoming CEO, Bresch served as Mylan's President, where she was responsible for the day-to-day operations of the company. Before that, she served as Mylan's Chief Operating Officer and Chief Integration Officer, leading the integration of the acquisitions of Matrix Laboratories and Merck KGaA's generics business. Ms Bresch served two terms as Chairman of the Generic Pharmaceutical Association.

Ms Bresch earned her undergraduate degree from West Virginia University.